GLP-1 RAs, originally developed for glycemic control in type 2 diabetes, have demonstrated mechanistic plausibility and emerging clinical efficacy in modulating key pathophysiological processes implicated in depression, including insulin resistance, neuroinflammation, and reward system dysregulation. This evidence concerns the gene GCG and depressive disorder.